SAGE vs. ALXO, PLRX, ARCT, ELVN, OCUL, SPRY, AUPH, LBPH, TNGX, and ARQT
Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include ALX Oncology (ALXO), Pliant Therapeutics (PLRX), Arcturus Therapeutics (ARCT), Enliven Therapeutics (ELVN), Ocular Therapeutix (OCUL), ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), Longboard Pharmaceuticals (LBPH), Tango Therapeutics (TNGX), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Sage Therapeutics (NASDAQ:SAGE) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Sage Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
In the previous week, Sage Therapeutics had 17 more articles in the media than ALX Oncology. MarketBeat recorded 22 mentions for Sage Therapeutics and 5 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.30 beat Sage Therapeutics' score of -0.35 indicating that ALX Oncology is being referred to more favorably in the news media.
ALX Oncology has lower revenue, but higher earnings than Sage Therapeutics. ALX Oncology is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
ALX Oncology has a net margin of 0.00% compared to Sage Therapeutics' net margin of -626.32%. Sage Therapeutics' return on equity of -54.41% beat ALX Oncology's return on equity.
Sage Therapeutics currently has a consensus target price of $39.28, indicating a potential upside of 189.23%. ALX Oncology has a consensus target price of $18.83, indicating a potential upside of 11.64%. Given Sage Therapeutics' higher possible upside, equities research analysts clearly believe Sage Therapeutics is more favorable than ALX Oncology.
99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 50.3% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sage Therapeutics received 585 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 68.31% of users gave Sage Therapeutics an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
Summary
Sage Therapeutics beats ALX Oncology on 9 of the 17 factors compared between the two stocks.
Get Sage Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sage Therapeutics Competitors List
Related Companies and Tools
